Citations

Showing 10 of 108162 citations.

Response to Letter to the Editor from Malone: “Proper Care of Transgender and Gender Diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective”
Walch, Abby , Davidge‐Pitts, Caroline , Tangpricha, Vin , Iwamoto, Sean J. , Safer, Joshua D. , Tangpricha, Vin , Iwamoto, Sean J , Safer, Joshua D , López, Ximena

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 27, 2021 | Volume: 106 | Issue: 8 | Pages: e3295-e3296

10.1210/clinem/dgab206 | PMID 33772302 Get It

Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS)
Kang, Daniel , Coffey, Christopher S. , Smith, Brian J, Yuan, Ying , Shi, Qian , Yin, Jun , Shi, Qian , Smith, Brian J

Mayo Clinic

Statistics in Medicine | March 27, 2021 | Volume: 40 | Issue: 12 | Pages: 2893-2921

10.1002/sim.8946 | PMID 33772843 Get It

Given the Food and Drug Administration's (FDA's) acceptance of master protocol designs in recent guidance documents, the oncology field is rapidly moving to address the paradigm shift to molecular subtype focused studies. Identifying new “marker‐based” treatments requires new methodologies to address the growing demand to conduct clinical trials in smaller molecular subpopulations, identify effective treatment and marker interactions, and control for false positives. We introduce our methodology, Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS), a two‐stage umbrella Phase II design with effect size clustering and information borrowing across multiple biomarker‐treatment pairs. HCOMBS was designed to reduce required sample size, differentiate between varying effect sizes, and control for operating characteristics in the multi‐arm setting. When compared to independently applied Simon's Optimal two‐stage design, we showed through simulations that HCOMBS required less participants per treatment arm with a well‐controlled family‐wise error rate and desirable marginal power. Additionally, HCOMBS features a statistical approach that simultaneously conducts clustering and hypothesis testing in one step. We also applied the proposed design on the alliance brain metastases umbrella trial.
NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages
Petersen, Ronald C. , Wiste, Heather J. , Weigand, Stephen D. , Fields, Julie A. , Geda, Yonas E. , Graff‐Radford, Jonathan , Knopman, David S. , Kremers, Walter K. , Lowe, Val J. , Therneau, Terry M. , Vemuri, Prashanthi , Knopman, David S. , Mielke, Michelle M , Stricker, Nikki H. , Vemuri, Prashanthi , Geda, Yonas E , Kremers, Walter K , Machulda, Mary M. , Mielke, Michelle M. , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | March 27, 2021 | Volume: 89 | Issue: 6 | Pages: 1145-1156

10.1002/ana.26071 | PMID 33772866 Get It

BackgroundTo operationalize the National Institute on Aging – Alzheimer's Association (NIA‐AA) Research Framework for Alzheimer's Disease 6‐stage continuum of clinical progression for persons with abnormal amyloid.MethodsThe Mayo Clinic Study of Aging is a population‐based longitudinal study of aging and cognitive impairment in Olmsted County, Minnesota. We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross‐sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS). We calculated frequencies of the stages using different cutoff points and assessed stability of the stages over 15 months.ResultsAmong 243 abnormal amyloid participants, the frequencies of the stages varied with age: 66 to 90% were classified as stage 1 at age 50 but at age 80, 24 to 36% were stage 1, 32 to 47% were stage 2, 18 to 27% were stage 3, 1 to 3% were stage 4 to 6, and 3 to 9% were indeterminate. Most stage 2 participants were classified as stage 2 because of abnormal ΔOBJ only (44–59%), whereas 11 to 21% had SCD only, and 9 to 13% had ΔNBS only. Short‐term stability varied by stage and OBJ cutoff points but the most notable changes were seen in stage 2 with 38 to 63% remaining stable, 4 to 13% worsening, and 24 to 41% improving (moving to stage 1).InterpretationThe frequency of the stages varied by age and the precise membership fluctuated by the parameters used to define the stages. The staging framework may require revisions before it can be adopted for clinical trials. ANN NEUROL 2021;89:1145–1156
The Development of a Novel Outpatient Infusion Therapy Center for Treatment of COVID-19 in a Rural Healthcare System
Malone, Edward, Krien, Joseph, Jorgenson, Betty, Bishop, Rachel, Tempelis, Jenny, Gilmer, Mary, Ring, David , Kujak-Coon, Heather, Jagim, Andrew R , Ring, David , Jagim, Andrew R.

Mayo Clinic

Journal of Primary Care & Community Health | March 27, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211007020 | PMID 33771055 Get It

Therapeutic interventions to manage symptoms of COVID-19 are continually evolving and being used in a variety of settings. In an attempt to reduce the potential for a high influx of hospital admissions for COVID-19 and mitigate the advancement of COVID-19 disease in infected patients, an outpatient therapy clinic for infusion therapy was established. The focus of the current paper is to outline the development of the outpatient treatment center, provide a detailed summary of workflow and discuss operational challenges and directions for the future.
Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments
Yoo, Ki Hyun , Tang, Jason J., Rashid, Mohammad Abdur, Cho, Chang Hoon , Corujo-Ramirez, Ana , Bae, Mun Gyeong, Brogren, Danielle, Hawse, John R. , Hou, Xiaonan , Weroha, S. John , Oliveros, Alfredo , Kirkeby, Lindsey A., Jang, Mi‐Hyeon , Choi, Jonghoon, Rashid, Mohammad Abdur, Choi, Jonghoon , Baur, Joseph A.

Mayo Clinic

Cancer Research | March 26, 2021 | Volume: 81 | Issue: 13 | Pages: 3727-3737

10.1158/0008-5472.can-20-3290 | PMID 33771896 Get It

Abstract Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic understanding underlying CICI pathophysiology. Using the platinum-based chemotherapy cisplatin as a model for CICI, we show here that cisplatin suppresses nicotinamide adenine dinucleotide (NAD+) levels in the adult female mouse brain in vivo and in human cortical neurons derived from induced pluripotent stem cells in vitro. Increasing NAD+ levels through nicotinamide mononucleotide (NMN) administration prevented cisplatin-induced abnormalities in neural progenitor proliferation, neuronal morphogenesis, and cognitive function without affecting tumor growth and antitumor efficacy of cisplatin. Mechanistically, cisplatin inhibited expression of the NAD+ biosynthesis rate-limiting enzyme nicotinamide phosphoribosyl transferase (Nampt). Selective restoration of Nampt expression in adult-born neurons was sufficient to prevent cisplatin-induced defects in dendrite morphogenesis and memory function. Taken together, our findings suggest that aberrant Nampt-mediated NAD+ metabolic pathways may be a key contributor in cisplatin-induced neurogenic impairments, thus causally leading to memory dysfunction. Therefore, increasing NAD+ levels could represent a promising and safe therapeutic strategy for cisplatin-related neurotoxicity. Significance: Increasing NAD+ through NMN supplementation offers a potential therapeutic strategy to safely prevent cisplatin-induced cognitive impairments, thus providing hope for improved quality of life in cancer survivors.
Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model
Fisher, Deborah A. , Saoud, Leila, Rutten, Lila J. Finney , Brooks, Durado, Finney Rutten, Lila J , Limburg, Paul J. , Ozbay, A. Burak

Mayo Clinic

Current Medical Research and Opinion | March 26, 2021 | Volume: 37 | Issue: 6 | Pages: 1005-1010

10.1080/03007995.2021.1908244 | PMID 33769894 Get It

Efficacy of Combining Aggressive Hydration With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
Brahmbhatt, Bhaumik , Reddy, Chakradhar, Devani, Kalpit , Radadiya, Dhruvil , Reddy, Chakradhar

Mayo Clinic

Journal of Clinical Gastroenterology | March 26, 2021 | Volume: 56 | Issue: 3 | Pages: e239-e249

10.1097/mcg.0000000000001523 | PMID 33769395 Get It

Postendoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common complication of endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). No randomized controlled trial (RCT) has compared the efficacy of the American Society of Gastrointestinal Endoscopy and European Society of Gastrointestinal Endoscopy recommended interventions for PEP prevention. We assessed the effectiveness of these interventions using network meta-analysis. PubMed, EMBASE, and Cochrane databases were searched to identify RCTs investigating guideline-recommended interventions and their combinations [rectal nonsteroidal anti-inflammatory drugs (NSAIDs): indomethacin or diclofenac, pancreatic stent (PS), aggressive hydration (AH), sublingual nitrate) for PEP prevention. We performed direct and Bayesian network meta-analysis, and the surface under the cumulative ranking curve to rank interventions. Subgroup network meta-analysis for high-risk populations was also performed. We identified a total of 38 RCTs with 10 different interventions. Each intervention was protective against PEP on direct and network meta-analysis compared with controls. Except AH+diclofenac and NSAIDs+ sublingual nitrate, AH+indomethacin was associated with a significant reduction in risk of PEP compared with PS [odds ratio (OR), 0.09; credible interval (CrI), 0.003-0.71], indomethcin+PS (OR, 0.09; CrI, 0.003-0.85), diclofenac (OR, 0.09; CrI, 0.003-0.65), AH (OR, 0.09; CrI, 0.003-0.65), sublingual nitrate (OR, 0.07; CrI, 0.002-0.63), and indomethacin (OR, 0.06; CrI, 0.002-0.43). AH with either rectal NSAIDs or sublingual nitrate had similar efficacy. AH+indomethacin was the best intervention for preventing PEP with 95.3% probability of being ranked first. For high-risk patients, although the efficacy of PS and indomethacin were comparable, PS had an 80.8% probability of being ranked first. AH+indomethacin seems the best intervention for preventing PEP. For high-risk patients, PS seems the most effective strategy. The potential of combination of interventions need to be explored further.
Role of Maternal Laparoscopy in Fetal Surgery
Willborg, Brooke E. , Cope, Adela G. , Burnett, Tatnai L. , Ruano, Rodrigo

Mayo Clinic

Videoscopy | March 26, 2021 | Volume: 31 | Issue: 2 | Pages: No page available

10.1089/vor.2020.0703 Get It

Antifungal Prophylaxis for Adult Recipients of Veno-Venous Extracorporeal Membrane Oxygenation: A Cautionary Stance During the COVID-19 Pandemic
Epelbaum, Oleg , Carmona, Eva M. , Evans, Scott E. , Hage, Chadi A. , Jarrett, Benjamin, Knox, Kenneth S. , Pennington, Kelly M. , Carmona, Eva M , Limper, Andrew H.

Mayo Clinic

ASAIO Journal | March 26, 2021 | Volume: 67 | Issue: 6 | Pages: 611-613

10.1097/mat.0000000000001456 | PMID 33769344 Get It